Screening for colorectal cancer part 1: screening-tests and program design
Patera N, Schumacher I
Record ID 32013000021
English
Authors' recommendations:
- program design (quality) and participation rate matter
- choice of screening-test is of secondary importance
- CRC-screening is not simply about choosing the right initial test for screening
- effective CRC-screening is about establishing a quality assured screening-program integrating diagnosis, treatment and surveillance
- emphasis on quality focused human resource development of endoscopists
- uptake is the primary determinant of effectiveness for a screening-program
- level of regular participation and the resulting effective program-sensitivity has a greater influence than the sensitivity of a single performance of a screening-test particularly in the context of a population-based screening-program for slowly developing abnormalities (e.g. for CRC)
- study of determinants of participation rate warranted to inform program design
- quality of screening-program (narrower realm of screening plus integration of diagnosis – treatment – surveillance) affects desired outcome of mortality reduction and minimization of negative repercussions on screened population
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://eprints.hta.lbg.ac.at/981/1/HTA-Projektbericht_Nr.41a_Update_2012.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Humans
- Colorectal Neoplasms
- Mass Screening
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.